Ask the expert: Are online innovations the future of Parkinson’s treatment?
Author: Sophie BatesPublished: 14 May 2020
Prep: Cook: Serves:
In the latest in our Ask the Expert series, we speak with neurologist Joaquim Ferreira, about the importance of online resources for people with Parkinson’s during the Covid-19 pandemic and how the crisis has led to new forms of clinical communication
Could you tell us how online therapies for people with Parkinson’s are evolving?
Parkinson’s is complex in its clinical presentation – symptoms vary and the condition is not easy to understand, even by healthcare professionals. We are learning that simple aspects regarding the way the diagnosis is made and communicated have prognostic implications, so educating the Parkinson’s community is extremely important.
New healthcare concepts of multidisciplinary and home or community-based interventions are being evaluated in an attempt to define the best way of combining different therapeutic interventions. These new healthcare models include education components and should be addressed in the same way as other health conditions. Likewise, the use of web-based interventions appears as an efficient way to target and hopefully benefit many people with Parkinson’s.
Why is accessing online information about Parkinson’s particularly important during the Covid-19 crisis?
Parkinson’s is a condition that needs continuous follow-up and management, so it’s critical to maintain care and monitoring even when we cannot access clinics in the same way. Keeping up therapeutic programmes is very important to avoid losing the benefits. We have been learning that non-pharmacological treatments – for instance, physiotherapy and speech therapy, have a duration of effect like any drug, so once they are stopped, the effects start to disappear. In the same way that we should not stop taking anti-parkinsonian medication (like drugs that release dopamine or mimic the action of dopamine) without professional advice, therapeutic treatments shouldn’t be stopped.
What role can other online resources play for people with Parkinson’s during the crisis?
The available resources are not enough for the mission we have. Not everything during the pandemic has been negative – this period has forced us to discover new ways that we can be involved in the care of individuals. The use of online tools has allowed us to perform consultations and therapeutic sessions – and we have been able to conclude surprisingly quickly that these tools work.
In terms of the future, online resources will allow a better documentation of what happens in the daily routines of people with Parkinson’s. Physicians will be able to access the real data of individuals from the information collected during face-to-face consultations, which will mean a ‘closer’ follow up – merging outpatient consultations with online interventions and support. So, in my opinion, online visits and sessions are here to stay.
You are the founder of neurological disorders centre Campus Neurológico Sénior (CNS). Could you tell us about the CNS Academy videos and how they benefit people with Parkinson’s?
The main purpose of CNS is to reunite quality clinical activity, leading research projects and training health professionals. The CNS Academy videos present the great work being done by our professionals and highlight our perception that there’s still a huge need for simple and high-quality information for everyone with Parkinson’s. We created these videos because we felt compelled to share the expertise of our dedicated and highly trained professionals – so that others can benefit from their knowledge.
The topics – which were suggested by healthcare professionals working at CNS – try to cover the most frequent and relevant problems that can be addressed by cartoons. They include educational videos on how to manage medication, home safety, how to help the caregiver, speech problems, gait problems etc. The videos’ objective is not just to propose simple tips, but to promote the increase of physical and cognitive training at home, to complement all other interventions applied by professionals in clinics.
How can people ensure that the information they find online about Parkinson’s is accurate and up to date?
It can be extremely difficult to differentiate between high quality data and misinformation. The easiest and most effective way to filter the good from bad is to always favour information published through associations – for instance, the European Parkinson’s Disease Association (EPDA), Parkinson’s Foundation, or organisations with scientific boards validating their content.
It’s important to be cautious when reading news that presents amazing or almost miraculous treatments. We all hope that in the near future we will have huge therapeutic achievements to share – but they will be presented through publications in scientific journals, scientific societies or congresses, and not posted on the web by people who do not have a solid scientific curriculum.
This difficult period reinforces the need for a close and fruitful collaboration between all. It clarifies the need to be humble when dealing with our health and the uncertainties we still have in many fields of knowledge. These strange and unexpected times will end soon, and we should learn from them.
Need to know
Joaquim Ferreira is a neurologist based in Lisbon, Portugal. He has worked in the field of movement disorders and Parkinson’s for the past 25 years and is a professor of neurology and clinical pharmacology at the University of Lisbon. He is also the founder of Campus Neurológico Sénior (CNS) in Portugal, a neurological disorders centre that focuses on multidisciplinary care for people with Parkinson’s.
For more advice on living well with Parkinson’s, please visit the EPDA website.
We round up the top Parkinson’s news stories from around the globe
6 days ago
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”
Could a prostate drug lower the risk of Parkinson’s disease?
Researchers in the US, Denmark and China have found that a type of medication used to treat enlarged prostate, known as alpha-blockers, is associated with a lower risk of Parkinson’s disease. As part of the study, the research team analysed patient data from 150,000 men using medications like the alpha-blocker terazosin – which has previously been shown to slow Parkinson’s disease progression in animals – and compared their findings to data from 150,000 men using the alpha-blocker tamsulosin. They found that men taking terazosin were 12 to 37% less likely to develop Parkinson’s disease. Jacob Simmering, corresponding author of the study, said: “Despite the relative differences in population and health care system structure, we found a similar protective effect in both [the US and Denmark]. “If these results are confirmed through further investigation, especially a randomised clinical trial, terazosin may provide neuroprotection and potentially prevent – and not just manage…